Studies related to Symptoms of Multiple Sclerosis and Marijuana

Psychopathological And Cognitive Effects Of Therapeutic Cannabinoids In Multiple Sclerosis: A Double-blind, Placebo Controlled, Crossover Study

In a double-blind crossover study (one group participating as their own controls) where persons with multiple sclerosis used marijuana or placebo (sublingual application of both to a point where perceived muscular spasticity was reduced) noted that there were no differences between groups on cognitive tests or psychopathological scores.

Given tests were the PASAT (Paced Auditory Serial Additional Test) and MSFC (Multiple Sclerosis Functional Composite) with the former testing auditory information processing speed and calculation ability.

General symptoms of MS (fatigue, leg and arm function, quality of life, physical impairment) did not differ between study periods.

Cannabinoids In Multiple Sclerosis (CAMS) Study: Safety And Efficacy Data For 12 Months Follow Up

Following the completion of the CAMS trial and following up patients who chose to maintain THC / cannabis / placebo treatment for up to a year, it was noted that the benefits towards self-reported muscular health persisted while benefits appeared (to a clinically mild degree) on Ashworth rating scales. Fatigue and Energy, but not irritability or depression, also appeared to be benefited after 27 and 52 weeks.

Cannabinoids For Treatment Of Spasticity And Other Symptoms Related To Multiple Sclerosis (CAMS Study): Multicentre Randomised Placebo-controlled Trial

In persons with multiple sclerosis given either pure THC or cannabis extracts over 15 weeks, supplementation failed to result in any improvements in physician-assessed physical mobility although patient-reported stiffness, pain, spasticity, and spasms (but not shake/tremor) appeared to be improved with supplementation. This led to improvements in sleep quality, although symptoms of fatigue and depression were unaffected.

Multiple Sclerosis And Extract Of Cannabis: Results Of The MUSEC Trial

In persons with multiple sclerosis supplementing 25mg THC daily over the course of 10 weeks, the overall clinical response rate for muscle stiffness reductions reached 29.4% with THC which was significantly greater than the 15.7% seen in placebo.